| 莫西沙星治疗慢性支气管炎急性发作的前瞻性研究 |
| 投稿时间：2004-06-02 点此下载全文 |
| 引用本文：马伟斌,江荣林,毛文炜.莫西沙星治疗慢性支气管炎急性发作的前瞻性研究[J].药学实践杂志,2005,(1):30~32 |
| 摘要点击次数: 1158 |
| 全文下载次数: 956 |
|
|
| 中文摘要:目的 研究莫西沙星对慢性支气管炎急性发作(AECB)的疗效.方法 对AECB患者随机分成二组,一组口服莫西沙星400mg,gd×6d,另一组口服克拉霉素500mg,bid×6d,观察临床疗效和细菌清除状况以及不良反应.结果 莫西沙星治疗组和克拉霉素治疗组病人的临床总有效率分别为93.1%和87.9%,差异无显著性(P<0.05);支气管周围炎症吸收率分别为84.7%和71.2%,差异有显著性(P>0.05);痰中致病菌清除率分别为88.9%和72.1%,差异有显著性(P>0.05);不良反应发生率分别为1.4%和13.6%,差异有显著性(P>0.05).结论 在治疗AECB时,莫西沙星与克拉霉素比较,两者的临床疗效基本相似,但其支气管周围炎症吸收状况前者优于后者,痰中致病菌清除率更高,更具依从性和耐受性. |
| 中文关键词:慢性支气管炎急性发作 莫西沙星 克拉霉素 |
| |
| Prospective study on moxifloxacin in treatment of acute exacerbations of chronic bronchitis (AECB) |
|
|
| Abstract:Objective To study the effect of moxifloxacin in patients with AECB.Methods 143 patients with AECB were divided into two groups with randomization.The first group took moxifloxacin 400mg×6 days po (per os), and the second group took clarithro-mycin 500mg×6 days po.The clinical effect, the clearance state of bacteria and the adverse reactions were observed.Results The total clinical effective rate was 93.1%,87.9% with the group of moxifloxacin and clarithromycin respectively, there was no significant difference(P<0.05), the absorptivity of infection around bronchia was 84.7%, 71.2% respectively, there was significant difference (P<0.05 ), the clearance of pathogenic bacteria in sputum was 88.9%, 72.1 % respectively, there was significant difference (P<0.05), the occurrence rate of adverse reactions was 1.4%,13.6% respectively, there was significant difference (P<0.05).Conclutions:The clinical effect was almost similar between moxifloxacin and clarithromycin, while, the absorption state of infection around bronchia of moxifloxacin was better than clarithromycin, and had much higher in the clearance of pathogenic bacterium in sputum, also, moxifloxacin has better compliance and tolerance. |
| keywords:acute exacerbations of chronic bronchitis moxifloxacin clarithromycin |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
| 关闭 |
|
|
|
